Keyword: Tecfidera

After Biogen's Alzheimer's disease trial failure last month, executives are working to ease investor concern about the company's future.

Think the success of several megablockbusters such as AbbVie’s Humira means the anti-inflammation market is fully saturated? Think again.

Rejected in 2011, Mavenclad won FDA approval with a label that's not ideal—but that doesn't necessarily hurt its blockbuster odds, says one analyst.

With the aducanumab flop, shareholders are questioning management’s strategy—and an uncertain pipeline isn’t helping, either.

Biogen has been working hard to build out its pipeline, but as that effort plays out, the biotech faces a new patent challenge to its top moneymaker.

After releasing strong earnings, Biogen's executives did their best to reassure analysts that the success of the pipeline won't rely solely on Alzheimer's.

MyHealthTeams specialized social networks are adding pharma-sponsored resource centers with its most recent in spondyloarthritis.

Biogen grew sales 9% in the second quarter, beating Street expectations, but analysts on the company's conference call were focused elsewhere.

A patent ruling for Novartis will give Celgene time to secure FDA approval for its Gilenya rival and persuade physicians that it's a safer MS pill.

NICE is now endorsing Ocrevus for NHS coverage in relapsing-remitting MS and will deliver a decision on the primary progressive form soon.